Coeptis Therapeutics is undergoing a complete corporate metamorphosis. Shareholders have approved a definitive merger agreement with Z Squared Inc., triggering a fundamental shift in the company’s core business away from biopharmaceuticals and toward technology infrastructure. This move represents a radical strategic departure for the entire organization.
New Ownership and Market Listing
Should this new direction find favor with investors? Upon closing the transaction, the current owners of Z Squared are set to control approximately 79% of the combined entity. Existing Coeptis shareholders will retain a 21% stake. The company has applied for a Nasdaq listing under a fresh ticker symbol, though final approval from the exchange remains pending.
This transition from a biotechnology developer to a participant in the digital asset arena fundamentally alters the investment risk profile. While the original research pipelines will continue separately, the future valuation of Z Squared Inc. will be primarily tied to cryptocurrency market dynamics and the operational efficiency of its mining infrastructure.
A Core Focus on Dogecoin and Litecoin
Ad
Should investors sell immediately? Or is it worth buying Coeptis Therapeutics?
The merger will make Z Squared a subsidiary, with the parent company expected to operate under the name Z Squared Inc. The new central business segment involves managing thousands of ASIC miners dedicated to the Dogecoin and Litecoin networks. With the digital infrastructure valued at around $660 million, the company aims to establish itself as the largest publicly-listed Dogecoin mining operation in the United States.
This strategic pivot launches the firm into the digital asset infrastructure sector—a market characterized by dynamics wholly different from the clinical development of therapeutic drugs. The deal’s completion is still subject to customary closing conditions.
Spin-Off of Legacy Biopharma Assets
The existing biopharma business unit will be legally separated as part of the restructuring. Shareholders of record as of January 2, 2026, will receive shares in this new, independent company through a stock dividend. The biotechnology division carries a valuation of about $75 million, allowing investors to maintain exposure to the potential value creation of the cell therapy and oncology programs.
Ad
Coeptis Therapeutics Stock: New Analysis – 28 February
Fresh Coeptis Therapeutics information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.
Read our updated Coeptis Therapeutics analysis…
